About Calibra Medical
Calibra Medical is developing medical devices and technologies designed to make insulin therapy easier and more discreet for patients with Type I and Type II diabetes. Calibra Medical's insulin delivery device aims to be small and wearable and contains a 3-day supply of insulin that can be actuated through clothing. Calibra Medical's insulin delivery device is intended to replace what the company believes are the existing complicated, programmable pumps.Calibra Medical's first product, Finesse, is designed to improve mealtime insulin therapy delivery. Calibra Medical's goal with Finesse is to improve care for people with diabetes by simplifying insulin delivery, thereby improving patient adherence to their physician's treatment recommendations. Finesse is a small plastic device designed to adhere comfortably to a patient's skin. Per Calibra, Finesse is able to hold and deliver prescribed amounts of insulin over several days while remaining in place throughout a patient's daily activities, including showering, exercising and sleeping. The Finesse insulin delivery device operates through a patient's clothing and is designed to quickly deliver common dosage quantities.
Missing: Calibra Medical's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Calibra Medical's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Expert Collections containing Calibra Medical
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Calibra Medical is included in 3 Expert Collections, including Medical Devices.
Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.
Calibra Medical Patents
Calibra Medical has filed 1 patent.
Dosage forms, Drug delivery devices, Medical equipment, Insulin therapies, Actuators
Dosage forms, Drug delivery devices, Medical equipment, Insulin therapies, Actuators
Latest Calibra Medical News
Jul 18, 2018
CeQur buys assets from Calibra Medical X CeQur has acquired select assets of Calibra Medical, one of the Johnson & Johnson Diabetes Care Companies. Image: Calibra’s FDA-approved device for adults with diabetes who require insulin. Subscribe to our email newsletter The transaction includes an exclusive worldwide license for the wearable, on-demand insulin delivery system previously known as OneTouch Via. The Calibra system enables people with diabetes to discreetly and conveniently deliver rapid-acting insulin at mealtime. Financial terms were not disclosed. “CeQur is dedicated to simplifying insulin dosing for people with diabetes, so that they can live healthier, more satisfying lives,” said Robert Farra, chief executive officer of CeQur. “Clinical studies and real-world experience have shown that wearable, on-demand insulin delivery provides an ideal solution to the pervasive challenge of mealtime insulin delivery. The Calibra device is a perfect complement to PAQ, our basal and bolus insulin-infusion device. Both wearable devices provide simple, discreet, three-day insulin delivery without the barriers and discomfort created by injections.” CeQur plans to launch Calibra’s insulin delivery device under a new name in mid-2019, following transfer of manufacturing equipment. “This device will enable us to begin reaching the diabetes community with simple, discreet, three-day insulin delivery that will free people from having to inject multiple times per day,” said Farra. Two million people with type 2 diabetes in the United States take multiple daily insulin injections (MDI) to control their blood glucose levels (HbA1c). Clinical practice guidelines published by the American Diabetes Association generally point to HbA1c levels below 7 percent as reasonable targets to help prevent diabetes complications. An estimated 70 percent of insulin users in the United States do not achieve this goal, primarily due to missed insulin injections. Lifestyle restrictions, injection challenges and social stigma are all barriers to consistent and appropriate insulin therapy. Results of a global 62-site clinical study presented at the American Diabetes Association 2018 Scientific Sessions comparing the Calibra device to insulin pens to initiate and maintain bolus insulin dosing among 278 people with type 2 diabetes showed that this device provided positive clinical benefits with less glycemic variability than pens, significantly higher ease-of-use and patient satisfaction scores, and similar safety. “Basal and bolus insulin therapy works when we have the tools to determine the appropriate insulin doses and deliver them in a convenient way,” said Richard M. Bergenstal, MD, endocrinologist and executive director of the International Diabetes Center in Minneapolis, Minnesota. “Results from the Calibra clinical study were quite impressive, showing that the device provides an easy way for patients to deliver bolus insulin at mealtimes on top of an individualized basal insulin injection. Having options available for patients that makes insulin delivery easier, more discreet and convenient is one way to help improve diabetes management.” “The Calibra device is well designed with impressive clinical results,” said Eric Milledge, executive chairman of CeQur. “The number of people with diabetes who require insulin will continue to grow. Given the proven benefits of this device, as well as the range of patients it can support, CeQur will improve the health and simplify the lives of these individuals.” CeQur is developing and commercializing advanced yet simple-to-use insulin delivery devices that make it easier for people living with diabetes to adhere to therapy and stay in control of their disease. The Company’s simple, three-day, wearable devices provide freedom from multiple daily insulin injections. Source: Company Press Release
Calibra Medical Frequently Asked Questions (FAQ)
When was Calibra Medical founded?
Calibra Medical was founded in 2004.
Where is Calibra Medical's headquarters?
Calibra Medical's headquarters is located at 220 Saginaw Drive, Redwood City.
What is Calibra Medical's latest funding round?
Calibra Medical's latest funding round is Acquired - II.
How much did Calibra Medical raise?
Calibra Medical raised a total of $64.43M.
Who are the investors of Calibra Medical?
Investors of Calibra Medical include CeQur, Lifescan, Frazier Healthcare Partners, Three Arch Partners, Skyline Ventures and 4 more.
Who are Calibra Medical's competitors?
Competitors of Calibra Medical include InterRad Medical, Broncus Medical, Svelte Medical Systems, Endologix, REGENESIS BIOMEDICAL and 16 more.
Compare Calibra Medical to Competitors
Axial Biotech, founded in 2002 by a group of spine surgeons and geneticists, is focused on the use of genetics and the development of minimally invasive fusionless devices to advance the diagnosis and treatment of diseases and deformities of the human spine. Axial is a company to pursue DNA-based pre-symptomatic and prognostic tests for common spinal conditions which will augment current clinical and surgical practices. In its initial genetic product development initiative, Axial has made progress towards the discovery of a location in the human genome that is associated with adolescent idiopathic scoliosis. In addition, Axial's founders have developed five motion preserving, fusionless surgical devices (including such device currently being implanted in humans) that have the promise of expanding the current treatable scoliosis patient population by a factor of ten. Axial intends to use its genetic intellectual property in the development of bio-mechanical devices, and to apply its gene discovery/product development methodology to other spinal diseases. Axial (www.axialbiotech.com) is located in Salt Lake City, Utah.
Endologix is a developer and manufacturer of minimally invasive treatments for vascular diseases. Endologix is focusing on the development and marketing of its patented technology for the treatment of Abdominal Aortic Aneurysms (AAA). An aneurysm is a weakening of the wall of the aorta, the largest artery of the body. Aortic aneurysm disease is a cause of death in the United States and it is estimated that 1.7 million persons over 55 years of age have an AAA. Each year, physicians diagnose approximately 200,000 people in the United States with AAA. Endologix is currently marketing its Powerlink Delivery System a, one-piece endoluminal stent graft (ELG) used in treating AAA that has significant advantages when compared with marketed stent alternatives. Powerlink has been commercially available in Europe since 1999. FDA approval for the Powerlink AAA stent graft was received on October 29, 2004. The Powerlink superior design is covered by 17 U.S. patents with 361 allowed claims; the technology is designed to overcome shortcomings of first-generation ELGs. The device is for sale in the United States and selected international markets. Endologix is a publicly-held company trading on NASDAQ: ELGX. The company's corporate office is located in Irvine, California.
Varix Medical Corporation, located in Sunnyvale, Calif., is a medical device company focused on developing products for the minimally invasive treatment of chronic venous insufficiency, commonly referred to as "varicose veins." For patients with advanced stages of varicose veins, laser- and RF-based (radiofrequency) treatments have been developed, but each device has deficiencies making them less-than-optimal solutions. Varix Medical's platform technology will enable physicians to efficiently and effectively treat more types of diseased veins than is currently possible when using either laser or RF devices. Additional treatable vessels include tortuous sub-truncal vessels and other visible smaller varicose veins. The Varix platform employs a vapor-based endovenous ablation system that will consist of a disposable catheter, a catheter introducer or delivery system, and a reusable vapor generator. RCT and Coronis Medical Ventures LLC., formed Varix in August 2007 and acquired the technology under license from Tsunami MedTech LLC. Coronis and RCT have been the primary in investors in Varix.
Emphasys Medical has developed an innovative device called the Emphasys Endobronchial Valve* (EBV). The EBV is implanted in the diseased portions of the lung and utilizes a one-way valve to prevent air from entering the diseased lung segments during inhalation yet allows trapped air to vent during exhalation. This design is intended to allow inhaled air to be redirected to the healthier, functional parts of the lung. The Emphasys procedure is a minimally invasive treatment option in which the device is placed in selectively targeted areas of the affected lung determined by the extent of the emphysema damage.
Intersect Partners is a California based medical devices company. The company primarily produces intragastric balloons, stent-like neurological medical devices, and associated minimally invasive drug delivery and device systems.
CeQur is developing and commercializing advanced yet simple-to-use insulin delivery devices that make it easier for people living with type 2 diabetes to adhere to therapy and stay in control of their disease. The Company's fully optimized device, PaQ, is a three-day, wearable device that provides freedom from multiple daily insulin injections.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.